Avenda Health, a software and medical device company developing an
AI-based focal laser ablation system to offer patients a personalized
prostate cancer treatment, today announced the company will present
multiple abstracts at the Annual Meeting of the Engineering and Urology
Section (EUS), taking place during the 2019 American Urology Association
(AUA) Annual Meeting, May 3 – 6, in Chicago.
Avenda Health’s investigational, image-guided focal laser ablation
system is designed to treat localized prostate cancer in a urologist’s
office. In conjunction with AI-based margin prediction algorithms, it
uses a laser and a proprietary optical and thermal sensor to precisely
target and treat just the prostate tumor – not the entire prostate. The
goal is for this targeted ablation to minimize the impact on healthy
tissues, without compromising urinary or sexual function.
“Today’s standard treatment approaches typically involve removing or
treating the entire prostate gland. Our investigational technology is
office-based and uses imaging, artificial intelligence, and laser
ablation to treat only the tumor with a safety margin, minimizing side
effects on the patient,” said Shyam Natarajan, co-founder and CEO of
Avenda Health. “We look forward to sharing data with the urology
community at the EUS meeting that demonstrate the potential of our
AI-driven focal laser ablation technology in treating prostate cancer
while preserving quality of life.”
EUS at AUA presentations taking place May 5th at the Marriott Marquis
include:
-
“Development of an Office-Based Laser Ablation System for Prostate
Cancer” will be presented by Josh Shubert, Software Engineer, Avenda
Health.
– Poster Session #24, Great Lakes Ballroom B at 1:30 –
2:30 p.m. CT
-
“Improving Prostate Cancer Margin Prediction Through Machine
Learning,” awarded 2019 Best Paper by the Engineering and Urology
Society, will be presented by Dr. Alan Priester, David Geffen School
of Medicine, UCLA.
– Poster Session #36, Great Lakes
Ballroom B at 2:30 – 3:30 p.m. CT
-
“MRI Changes After In-Office Focal Cryoablation of Prostate Cancer: A
Pilot Study” will be presented by Steve Zhou, David Geffen School of
Medicine, UCLA.
– Poster Session #47, Great Lakes Ballroom B at
2:30 – 3:30 p.m. CT
Additionally, the company will be demonstrating its software and focal
laser ablation technology at booth #1413 throughout the duration of the
AUA meeting.
About Avenda Health
Avenda Health is the only image-guided ablation system (pending FDA
clearance) that leverages artificial intelligence to treat only the
tumor, minimizing the side effects of the treatment on the patient.
Unlike other options, this approach has the potential to offer patients
a personalized treatment performed in-office using local anesthesia,
potentially allowing them to quickly return to their daily activities
without compromising their quality of life. Also, because this is a
minimally invasive and local treatment, it doesn’t close the door for
future treatment options should patients need it.
For more information visit avendahealth.com
and follow on Twitter at @AvendaHealth.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190425005345/en/